SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2

(Amendment No. 1)*

Pain Therapeutics, Inc.

(Name of Issuer)

Common Stock (Title of Class of Securities)

> 69562K506 (CUSIP Number)

December 31, 2017 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☑ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 69562K506	13G	Page 1 of
---------------------	-----	-----------

1.	NAMES OF REPORTING PERSONS			
	Thomas A. Satterfield, Jr.			
2.	CHECK '	ТНІ	E APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a) (b) (c)			
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLACE OF ORGANIZATION			
	United States of America 5. SOLE VOTING POWER			
		3.	SOLE VOTING POWER	
NII IN/	IBER OF		39,472	
SHARES 6. SHARED VOTING POWER				
~	FICIALLY			
OW	NED BY		511,000	
	ACH	7.	SOLE DISPOSITIVE POWER	
	ORTING RSON			
	VITH		39,472	
•	VIIII	8.	SHARED DISPOSITIVE POWER	
			511,000	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	550,472			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	8.3%*			
12.	2. TYPE OF REPORTING PERSON			
	IN			
1	1 '			

^{*} Based on 6,595,509 shares of Common Stock of the issuer outstanding as of October 27, 2017, as reported by the issuer in its Quarterly Report on Form 10-Q for the period ended September 30, 2017, filed with the Securities and Exchange Commission on November 1, 2017.

SCHEDULE 13G

Item 1.

(a) Name of Issuer:

Pain Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices:

7801 N. Capital of Texas Highway, Suite 260 Austin, TX 78731

Item 2.

(a) Name of Person Filing:

Thomas A. Satterfield, Jr.

(b) Address of Principal Business Office or, if none, Residence:

Thomas A. Satterfield, Jr. 2609 Caldwell Mill Lane Birmingham, Alabama 35243

(c) Citizenship:

Incorporated by reference from Item 4 of the Cover Page.

(d) Title of Class of Securities:

Incorporated by reference from the Cover Page.

(e) CUSIP Number:

Incorporated by reference from the Cover Page.

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable.

Item 4. Ownership.

(a) Amount beneficially owned:

Incorporated by reference from Item 9 of the Cover Page.

(b) Percent of class:

Incorporated by reference from Item 11 of the Cover Page.

- (c) Number of shares as to which such person has:
 - Sole power to vote or to direct the vote
 Incorporated by reference from Item 5 of the Cover Page.
 - (ii) Shared power to vote or to direct the vote

 Incorporated by reference from Item 6 of the Cover Page.
 - (iii) Sole power to dispose or to direct the disposition of Incorporated by reference from Item 7 of the Cover Page.
 - (iv) Shared power to dispose or to direct the disposition of Incorporated by reference from Item 8 of the Cover Page.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 12,500 shares are held jointly with Mr. Satterfield's spouse; 5,000 shares are held individually by Mr. Satterfield's spouse; 55,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation wholly owned by Mr. Satterfield and of which he serves as President; and 210,000 shares are held by Caldwell Mill Opportunity Fund, a fund managed by an entity in which Mr. Satterfield owns a 50% interest and for which he serves as Chief Investment Manager. Additionally, Mr. Satterfield has limited powers of attorney for voting and disposition purposes with respect to the following shares: A.G. Family L.P. (200,000 shares); Jeanette Satterfield Kaiser (15,000 shares); Richard W. Kaiser (6,000 shares); and David A. Satterfield (7,500 shares). These individuals and entities have the right to receive or the power to direct the receipt of the proceeds from the sale of their respective shares.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP No. 69562K506 13G Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 12, 2018

Date

/s/ Thomas A. Satterfield, Jr.

Thomas A. Satterfield, Jr.